Biomark Diagnostics（20B）株式概要バイオマーク・ダイアグノスティックス社は、がん領域に特化した企業であり、がんを検出、監視、治療するためのがん診断プラットフォームを開発している。 詳細20B ファンダメンタル分析スノーフレーク・スコア評価0/6将来の成長0/6過去の実績0/6財務の健全性4/6配当金0/6リスク分析キャッシュランウェイが1年未満である 過去5年間で収益は年間8.5%減少しました。 収益が 100 万ドル未満 ( CA$92K )German市場と比較して、過去 3 か月間の株価の変動が非常に大きい+1 さらなるリスクすべてのリスクチェックを見る20B Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair Value€Current Price€0.344.3k% 割高 内在価値ディスカウントEst. Revenue$PastFuture-2m354k2016201920222025202620282031Revenue CA$353.6kEarnings CA$64.3kAdvancedSet Fair ValueView all narrativesBiomark Diagnostics Inc. 競合他社Genetic AnalysisSymbol: DB:8V8Market cap: €42.7mRespiratoriusSymbol: DB:HF00Market cap: €20.5m2investSymbol: DB:2INVMarket cap: €45.2mDarwinSymbol: MUN:7V0Market cap: €74.4m価格と性能株価の高値、安値、推移の概要Biomark Diagnostics過去の株価現在の株価€0.3452週高値€0.4252週安値€0.15ベータ-0.291ヶ月の変化1.78%3ヶ月変化2.38%1年変化105.99%3年間の変化111.04%5年間の変化37.60%IPOからの変化-47.56%最新ニュースお知らせ • Jan 16Biomark Diagnostics Inc. Announces Publication of Peer-Reviewed Validation of Machine Learning Models for Lung Cancer Detection in Frontiers in OncologyBioMark Diagnostics Inc. announced that its long-term investment in integrating artificial intelligence and machine learning into metabolomic profiling has achieved a major milestone. As the global healthcare investment community is focused on the transformative power of AI at the J.P. Morgan Healthcare Conference, BioMark has received this week notification that its research regarding a machine learning-driven predictive model for lung cancer detection has been accepted for publication in the prestigious, peer-reviewed journal Frontiers in Oncology. The accepted article, titled "Translational impact of machine learning-driven predictive modeling with pathway-based plasma metabolomic biomarkers for lung cancer detection," represents a successful realization of BioMark's strategy to utilize advanced computational tools to enhance diagnostic precision. This achievement validates the company's past capital allocation toward sophisticated AI infrastructure and confirms the scientific rigor of its metabolic pathway analysis. By moving beyond traditional biomarker identification and utilizing pathway-level data, BioMark has demonstrated a more comprehensive way to interpret the metabolic signatures of early-stage lung cancer. This research was made possible through a strategic collaboration with Dr. Maria Vaida and her team at the Harrisburg University of Science and Technology. The publication describes the use of pathway-based features from the Human Metabolome Database (HMDB) and explores the mechanistic drivers of cancer through interpretability tools such as SHAP analysis. This methodological approach allows for a deeper understanding of how specific metabolic pathways, such as those involved in nutrient processing and tumor growth, contribute to diagnostic models. The partnership with Harrisburg University has been instrumental in bridging the gap between complex data science and clinical application, ensuring that BioMark's technological foundation is built upon peer-reviewed, world-class scientific inquiry.お知らせ • Jan 01Biomark Diagnostics Inc. Appoints James Lavender as Board of Director, Effective December 22, 2025BioMark Diagnostics Inc. has appointed Mr. James Lavender to its Board of Directors following resolutions from the Annual General Meeting held on December 22, 2025. Mr. Lavender and his group were major investors in BioMark's most recent financing, completed in March 2025, underscoring strong insider alignment with the Company's growth strategy as it transitions from development to commercial execution. As BioMark accelerates its U.S. market entry, Mr. Lavender has been instrumental in opening high-level channels with state-level organizations and strategic investment groups across the United States. Mr. Lavender brings extensive software development and enterprise sales experience from leading technology companies, with a particular focus on scaling data-driven platforms. He has been a key advocate for expanding BioMark's use of Artificial Intelligence (AI) and Machine Learning (ML) to enhance clinical performance, automation, and scalability of metabolomics-based oncology diagnostics.お知らせ • Oct 14Biomark Diagnostics Inc., Annual General Meeting, Dec 22, 2025Biomark Diagnostics Inc., Annual General Meeting, Dec 22, 2025.お知らせ • May 12Biomark Diagnostics Inc. Announces the Publication of Pivotal Study as Part of the Special Issue Molecular Pathogenesis and Diagnostics of Lung Diseases of the International Journal of Molecular SciencesBioMark Diagnostics Inc. announced the publication of a pivotal study as part of the special issue Molecular Pathogenesis and Diagnostics of Lung Diseases of the International Journal of Molecular Sciences. The research, titled "Clinical Validation of Plasma Metabolite Markers for Early Lung Cancer Detection", provides significant external validation for BioMark's metabolomics and machine learning powered technology, particularly highlighting its high specificity and accuracy in detecting early-stage non-small cell lung cancer (NSCLC) and differentiating it from other non-cancerous lung conditions. The study utilized a large, clinically diverse patient cohort, analyzing 680 archived plasma samples in a discovery cohort and an independent set of 216 plasma samples for validation. A key strength of the research was the composition of the control group, which included not only healthy individuals but also patients with various non-cancerous lung diseases. This design allowed for a rigorous assessment of the test's ability to accurately identify lung cancer, minimizing the potential for false positives due to other lung conditions. The ability to detect lung cancer at its earliest stages significantly improves patient outcomes and survival rates. Current screening methods, such as low dose computed tomography (LDCT), have limitations, including lower sensitivity and specificity compared to regular CT scans, and can result in false positives leading to unnecessary invasive procedures. BioMark's minimally invasive blood test offers a promising approach to complement current screening methods, potentially leading to earlier interventions and better patient prognoses.お知らせ • Mar 31Biomark Diagnostics Inc. announced that it has received CAD 4.261195 million in fundingOn March 31, 2025, BioMark Diagnostics Inc. closed the transaction. The company announced that it has issued 4,593,984 units at an issue price of CAD 0.30 per unit for gross proceeds of CAD 1,378,195.2 in second and final tranche. The Units were issued at a price of CAD 0.30 per Unit, for aggregate gross proceeds of CAD 4,261,195. Each unit consists of one common share and one full purchase warrant. One whole share purchase warrant will entitle the holder thereof to purchase one common share at CAD 0.50 per share for a period of three years from the closing date of the private placement. The securities issued under the private placement will be subject to a period of four months and one day under the Canadian securities laws and subject to resale restrictions under the U.S. securities laws. Certain Insiders, Directors and Officers subscribed for a portion of this placement. Participation of the insiders of the Company in the private placement. The transaction included participation from United States and Europe. The transaction is oversubscribed.お知らせ • Mar 27Biomark Diagnostics Inc. announced a financing transactionBiomark Diagnostics Inc. announced a non-brokered private placement that it will issue units to receive funding on March 26, 2025. Each unit consists of one common share of company and one full purchase warrant. One whole share purchase warrant will entitle the holder thereof to purchase one common share at CAD 0.50 per share for a period of three years from the closing date of the private placement. The securities issued under the private placement will be subject to a period of four months and one day under the Canadian securities laws and subject to resale restrictions under the U.S. securities laws. No finders' fees were payable on the private placement. Under the first tranche, the company issued 9,610,000 units at a price of CAD 0.30 per Unit, for aggregate gross proceeds of CAD 2,883,000.最新情報をもっと見るRecent updatesお知らせ • Jan 16Biomark Diagnostics Inc. Announces Publication of Peer-Reviewed Validation of Machine Learning Models for Lung Cancer Detection in Frontiers in OncologyBioMark Diagnostics Inc. announced that its long-term investment in integrating artificial intelligence and machine learning into metabolomic profiling has achieved a major milestone. As the global healthcare investment community is focused on the transformative power of AI at the J.P. Morgan Healthcare Conference, BioMark has received this week notification that its research regarding a machine learning-driven predictive model for lung cancer detection has been accepted for publication in the prestigious, peer-reviewed journal Frontiers in Oncology. The accepted article, titled "Translational impact of machine learning-driven predictive modeling with pathway-based plasma metabolomic biomarkers for lung cancer detection," represents a successful realization of BioMark's strategy to utilize advanced computational tools to enhance diagnostic precision. This achievement validates the company's past capital allocation toward sophisticated AI infrastructure and confirms the scientific rigor of its metabolic pathway analysis. By moving beyond traditional biomarker identification and utilizing pathway-level data, BioMark has demonstrated a more comprehensive way to interpret the metabolic signatures of early-stage lung cancer. This research was made possible through a strategic collaboration with Dr. Maria Vaida and her team at the Harrisburg University of Science and Technology. The publication describes the use of pathway-based features from the Human Metabolome Database (HMDB) and explores the mechanistic drivers of cancer through interpretability tools such as SHAP analysis. This methodological approach allows for a deeper understanding of how specific metabolic pathways, such as those involved in nutrient processing and tumor growth, contribute to diagnostic models. The partnership with Harrisburg University has been instrumental in bridging the gap between complex data science and clinical application, ensuring that BioMark's technological foundation is built upon peer-reviewed, world-class scientific inquiry.お知らせ • Jan 01Biomark Diagnostics Inc. Appoints James Lavender as Board of Director, Effective December 22, 2025BioMark Diagnostics Inc. has appointed Mr. James Lavender to its Board of Directors following resolutions from the Annual General Meeting held on December 22, 2025. Mr. Lavender and his group were major investors in BioMark's most recent financing, completed in March 2025, underscoring strong insider alignment with the Company's growth strategy as it transitions from development to commercial execution. As BioMark accelerates its U.S. market entry, Mr. Lavender has been instrumental in opening high-level channels with state-level organizations and strategic investment groups across the United States. Mr. Lavender brings extensive software development and enterprise sales experience from leading technology companies, with a particular focus on scaling data-driven platforms. He has been a key advocate for expanding BioMark's use of Artificial Intelligence (AI) and Machine Learning (ML) to enhance clinical performance, automation, and scalability of metabolomics-based oncology diagnostics.お知らせ • Oct 14Biomark Diagnostics Inc., Annual General Meeting, Dec 22, 2025Biomark Diagnostics Inc., Annual General Meeting, Dec 22, 2025.お知らせ • May 12Biomark Diagnostics Inc. Announces the Publication of Pivotal Study as Part of the Special Issue Molecular Pathogenesis and Diagnostics of Lung Diseases of the International Journal of Molecular SciencesBioMark Diagnostics Inc. announced the publication of a pivotal study as part of the special issue Molecular Pathogenesis and Diagnostics of Lung Diseases of the International Journal of Molecular Sciences. The research, titled "Clinical Validation of Plasma Metabolite Markers for Early Lung Cancer Detection", provides significant external validation for BioMark's metabolomics and machine learning powered technology, particularly highlighting its high specificity and accuracy in detecting early-stage non-small cell lung cancer (NSCLC) and differentiating it from other non-cancerous lung conditions. The study utilized a large, clinically diverse patient cohort, analyzing 680 archived plasma samples in a discovery cohort and an independent set of 216 plasma samples for validation. A key strength of the research was the composition of the control group, which included not only healthy individuals but also patients with various non-cancerous lung diseases. This design allowed for a rigorous assessment of the test's ability to accurately identify lung cancer, minimizing the potential for false positives due to other lung conditions. The ability to detect lung cancer at its earliest stages significantly improves patient outcomes and survival rates. Current screening methods, such as low dose computed tomography (LDCT), have limitations, including lower sensitivity and specificity compared to regular CT scans, and can result in false positives leading to unnecessary invasive procedures. BioMark's minimally invasive blood test offers a promising approach to complement current screening methods, potentially leading to earlier interventions and better patient prognoses.お知らせ • Mar 31Biomark Diagnostics Inc. announced that it has received CAD 4.261195 million in fundingOn March 31, 2025, BioMark Diagnostics Inc. closed the transaction. The company announced that it has issued 4,593,984 units at an issue price of CAD 0.30 per unit for gross proceeds of CAD 1,378,195.2 in second and final tranche. The Units were issued at a price of CAD 0.30 per Unit, for aggregate gross proceeds of CAD 4,261,195. Each unit consists of one common share and one full purchase warrant. One whole share purchase warrant will entitle the holder thereof to purchase one common share at CAD 0.50 per share for a period of three years from the closing date of the private placement. The securities issued under the private placement will be subject to a period of four months and one day under the Canadian securities laws and subject to resale restrictions under the U.S. securities laws. Certain Insiders, Directors and Officers subscribed for a portion of this placement. Participation of the insiders of the Company in the private placement. The transaction included participation from United States and Europe. The transaction is oversubscribed.お知らせ • Mar 27Biomark Diagnostics Inc. announced a financing transactionBiomark Diagnostics Inc. announced a non-brokered private placement that it will issue units to receive funding on March 26, 2025. Each unit consists of one common share of company and one full purchase warrant. One whole share purchase warrant will entitle the holder thereof to purchase one common share at CAD 0.50 per share for a period of three years from the closing date of the private placement. The securities issued under the private placement will be subject to a period of four months and one day under the Canadian securities laws and subject to resale restrictions under the U.S. securities laws. No finders' fees were payable on the private placement. Under the first tranche, the company issued 9,610,000 units at a price of CAD 0.30 per Unit, for aggregate gross proceeds of CAD 2,883,000.お知らせ • Oct 21Biomark Diagnostics Inc., Annual General Meeting, Dec 27, 2024Biomark Diagnostics Inc., Annual General Meeting, Dec 27, 2024. Location: british columbia, richmond Canadaお知らせ • Sep 10Biomark Diagnostics Completes Testing of over 5,400 Subjects as Part of A Validation Study for Early Lung Cancer DetectionBioMark Diagnostics Inc. announced the successful completion of a significant clinical trial in collaboration with the Institut Universitaire de Cardiologie et de Pneumologie de Quebec. Over 5,400 patient samples were analyzed using BioMark's innovative lung cancer assay, demonstrating the test's potential to revolutionize early detection and improve patient outcomes. BioMark has partnered with a leading data analytics group possessing robust artificial intelligence and machine learning capabilities to analyze the vast amount of data collected during the trial. The results of the study will be presented at an upcoming medical conference and submitted for publication in a peer-reviewed journal. BioMark is committed to advancing the development of its lung cancer assay and making it available to patients in need as soon as possible. This innovative technology has the potential to significantly improve early detection rates and treatment outcomes for this devastating disease.Reported Earnings • Aug 30First quarter 2025 earnings released: CA$0.007 loss per share (vs CA$0.005 loss in 1Q 2024)First quarter 2025 results: CA$0.007 loss per share (further deteriorated from CA$0.005 loss in 1Q 2024). Revenue: CA$38.3k (down 3.6% from 1Q 2024). Net loss: CA$623.3k (loss widened 49% from 1Q 2024). Over the last 3 years on average, earnings per share has fallen by 1% per year whereas the company’s share price has remained flat.Reported Earnings • Jul 28Full year 2024 earnings released: CA$0.017 loss per share (vs CA$0.022 loss in FY 2023)Full year 2024 results: CA$0.017 loss per share (improved from CA$0.022 loss in FY 2023). Revenue: CA$163.2k (up 6.3% from FY 2023). Net loss: CA$1.43m (loss narrowed 23% from FY 2023). Over the last 3 years on average, earnings per share has fallen by 5% per year but the company’s share price has increased by 3% per year, which means it is well ahead of earnings.Reported Earnings • Mar 03Third quarter 2024 earnings released: CA$0.005 loss per share (vs CA$0.005 loss in 3Q 2023)Third quarter 2024 results: CA$0.005 loss per share (in line with 3Q 2023). Revenue: CA$41.5k (up 13% from 3Q 2023). Net loss: CA$406.8k (loss widened 3.3% from 3Q 2023). Over the last 3 years on average, earnings per share has fallen by 13% per year whereas the company’s share price has fallen by 17% per year.Board Change • Feb 01Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 3 highly experienced directors. Member of Advisory Board AI Berkeley was the last director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.New Risk • Jan 27New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of German stocks, typically moving 11% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (11% average weekly change). Negative equity (-CA$1.2m). Earnings have declined by 23% per year over the past 5 years. Revenue is less than US$1m (CA$159k revenue, or US$118k). Minor Risks Shareholders have been diluted in the past year (9.1% increase in shares outstanding). Market cap is less than US$100m (€15.1m market cap, or US$16.4m).New Risk • Jan 05New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 10% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Negative equity (-CA$1.2m). Earnings have declined by 23% per year over the past 5 years. Revenue is less than US$1m (CA$159k revenue, or US$119k). Minor Risks Share price has been volatile over the past 3 months (9.2% average weekly change). Shareholders have been diluted in the past year (10% increase in shares outstanding). Market cap is less than US$100m (€13.6m market cap, or US$14.9m).お知らせ • Dec 29Biomark Diagnostics Inc. announced that it has received CAD 1.9 million in fundingBiomark Diagnostics Inc announced that it has completed a non-brokered private placement of 7,600,000 units at a price of CAD 0.25 per unit for gross proceeds of CAD 1,900,000 on December 29, 2023. The securities issued under the private placement will be subject to a hold period of four months and one day. Each unit consists of one common share and one-full purchase warrant. One whole share purchase warrant will entitle the holder thereof to purchase one common share at CAD 0.45 per share for a period of three years from the closing date of the private placement, subject to an acceleration clause. Certain Insiders, Directors and Officers subscribed for a portion of this placement. No Finders' fees were payable on the private placement.Reported Earnings • Nov 29Second quarter 2024 earnings released: CA$0.003 loss per share (vs CA$0.006 loss in 2Q 2023)Second quarter 2024 results: CA$0.003 loss per share (improved from CA$0.006 loss in 2Q 2023). Revenue: CA$42.1k (up 2.9% from 2Q 2023). Net loss: CA$210.5k (loss narrowed 60% from 2Q 2023). Over the last 3 years on average, earnings per share has fallen by 15% per year but the company’s share price has increased by 27% per year, which means it is well ahead of earnings.お知らせ • Oct 13Biomark Diagnostics Inc., Annual General Meeting, Dec 22, 2023Biomark Diagnostics Inc., Annual General Meeting, Dec 22, 2023.Reported Earnings • Aug 30First quarter 2024 earnings releasedFirst quarter 2024 results: Revenue: CA$39.7k (up 11% from 1Q 2023). Net loss: CA$418.9k (flat on 1Q 2023). Over the last 3 years on average, earnings per share has fallen by 20% per year but the company’s share price has increased by 13% per year, which means it is well ahead of earnings.New Risk • Aug 04New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: €8.75m (US$9.65m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-CA$920k free cash flow). Share price has been highly volatile over the past 3 months (16% average weekly change). Negative equity (-CA$1.1m). Earnings have declined by 25% per year over the past 5 years. Revenue is less than US$1m (CA$153k revenue, or US$115k). Market cap is less than US$10m (€8.75m market cap, or US$9.65m).Reported Earnings • Aug 01Full year 2023 earnings released: CA$0.022 loss per share (vs CA$0.02 loss in FY 2022)Full year 2023 results: CA$0.022 loss per share (further deteriorated from CA$0.02 loss in FY 2022). Revenue: CA$153.5k (up 249% from FY 2022). Net loss: CA$1.84m (loss widened 27% from FY 2022). Over the last 3 years on average, earnings per share has fallen by 17% per year but the company’s share price has only fallen by 6% per year, which means it has not declined as severely as earnings.お知らせ • Jan 12BioMark Diagnostics Inc. Announces Update from Ongoing Clinical Trial Using its Lung Cancer Liquid Biopsy Test as it Prepares for Commercial LaunchBioMark Diagnostics Inc. announced several updates from ongoing clinical trial using the Company's liquid biopsy test for early cancer detection and monitoring of lung cancer. As clinical trial success relies on effective patient recruitment, BioMark is delighted to announce that enrollment for its pivotal lung cancer screening study exceeded 1,000 participants in less than one year. The lung cancer screening demonstration project led by Dr. Simon Martel, pulmonologist at the Quebec Heart and Lung Institute (Institut Universitaire de Cardiologie et Pneumologie de Québec- Université Laval - IUCPQ-UL), is intended to combine BioMark's metabolomics liquid biopsy test with radiomics and genetics biomarkers to help at-risk Quebecers get access to an accurate and accessible lung cancer screening program. The multimodal study was designed to recruit 4,000 participants from eight major hospitals across in Quebec, generating data that can support BioMark's implementation within the Province of Quebec. The Company also announces its first international patient recruited as part of a European prospective lung cancer screening trial in France known as the ILYAD study. BioMark's blood-based biomarker panel has been selected to define personalized lung cancer risk assessment in Europe's screen-eligible population who are most likely to benefit from a CT scan. The study is being conducted by Pr Sébastien Couraud, pulmonologist at the Hospices Civils de Lyon (HCL) and through a partnership with France- based TransDiag. Through the ILYAD study, the investigators are studying the participation rate during the initial round in the lung cancer screening program and assessing the performance of several blood- based biomarkers for the detection of cancers in screened individuals. The test being developed by the consortium would offer the opportunity to screen nearly 4 million individuals in France who are eligible for lung cancer screening under current European guidelines. These at-risk individuals are aged between 50 and 75 and have a history of heavy smoking. The Company intends to pursue clinical validation of the test as a laboratory developed test (LDT) in parallel with these ongoing studies. The BioMark Lung Cancer Risk Assessment Test will be available through its Quebec-based accredited laboratory, BioMark Diagnostic Solutions Inc., within approximately 9 - 12 months based on the completion of the ISO 15-189 certification.Is New 90 Day High Low • Mar 03New 90-day high: €0.21The company is up 141% from its price of €0.088 on 03 December 2020. The German market is up 8.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 6.0% over the same period.株主還元20BDE BiotechsDE 市場7D1.8%-1.0%0.6%1Y106.0%-11.9%0.2%株主還元を見る業界別リターン: 20B過去 1 年間で-11.9 % の収益を上げたGerman Biotechs業界を上回りました。リターン対市場: 20B過去 1 年間で0.2 % の収益を上げたGerman市場を上回りました。価格変動Is 20B's price volatile compared to industry and market?20B volatility20B Average Weekly Movement14.6%Biotechs Industry Average Movement8.8%Market Average Movement6.1%10% most volatile stocks in DE Market13.2%10% least volatile stocks in DE Market2.7%安定した株価: 20Bの株価は、 German市場と比較して過去 3 か月間で変動しています。時間の経過による変動: 20Bの weekly volatility ( 15% ) は過去 1 年間安定していますが、依然としてGermanの株式の 75% よりも高くなっています。会社概要設立従業員CEO（最高経営責任者ウェブサイト2014n/aRashid Ahmed Buxwww.biomarkdiagnostics.comBiomark Diagnostics Inc.は、癌領域に特化した企業で、癌の検出、モニタリング、治療のための癌診断プラットフォームを開発している。同社は肺がんの早期診断のためのリキッドバイオプシー代謝パネルアッセイに投資し開発している。同社はRubix LS社と戦略的提携を結び、肺がん検診を強化する診断ツールを開発し、乳房が密な女性のための乳がん検診プログラムを改善している。同社は2014年に法人化され、カナダのリッチモンドに本社を置いている。もっと見るBiomark Diagnostics Inc. 基礎のまとめBiomark Diagnostics の収益と売上を時価総額と比較するとどうか。20B 基礎統計学時価総額€34.47m収益（TTM）-€1.06m売上高(TTM)€57.33k630.6xP/Sレシオ-34.0xPER（株価収益率20B は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計20B 損益計算書（TTM）収益CA$91.77k売上原価CA$0売上総利益CA$91.77kその他の費用CA$1.79m収益-CA$1.70m直近の収益報告Dec 31, 2025次回決算日該当なし一株当たり利益（EPS）-0.016グロス・マージン100.00%純利益率-1,852.06%有利子負債／自己資本比率0%20B の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/21 07:33終値2026/05/21 00:00収益2025/12/31年間収益2025/03/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Biomark Diagnostics Inc. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
お知らせ • Jan 16Biomark Diagnostics Inc. Announces Publication of Peer-Reviewed Validation of Machine Learning Models for Lung Cancer Detection in Frontiers in OncologyBioMark Diagnostics Inc. announced that its long-term investment in integrating artificial intelligence and machine learning into metabolomic profiling has achieved a major milestone. As the global healthcare investment community is focused on the transformative power of AI at the J.P. Morgan Healthcare Conference, BioMark has received this week notification that its research regarding a machine learning-driven predictive model for lung cancer detection has been accepted for publication in the prestigious, peer-reviewed journal Frontiers in Oncology. The accepted article, titled "Translational impact of machine learning-driven predictive modeling with pathway-based plasma metabolomic biomarkers for lung cancer detection," represents a successful realization of BioMark's strategy to utilize advanced computational tools to enhance diagnostic precision. This achievement validates the company's past capital allocation toward sophisticated AI infrastructure and confirms the scientific rigor of its metabolic pathway analysis. By moving beyond traditional biomarker identification and utilizing pathway-level data, BioMark has demonstrated a more comprehensive way to interpret the metabolic signatures of early-stage lung cancer. This research was made possible through a strategic collaboration with Dr. Maria Vaida and her team at the Harrisburg University of Science and Technology. The publication describes the use of pathway-based features from the Human Metabolome Database (HMDB) and explores the mechanistic drivers of cancer through interpretability tools such as SHAP analysis. This methodological approach allows for a deeper understanding of how specific metabolic pathways, such as those involved in nutrient processing and tumor growth, contribute to diagnostic models. The partnership with Harrisburg University has been instrumental in bridging the gap between complex data science and clinical application, ensuring that BioMark's technological foundation is built upon peer-reviewed, world-class scientific inquiry.
お知らせ • Jan 01Biomark Diagnostics Inc. Appoints James Lavender as Board of Director, Effective December 22, 2025BioMark Diagnostics Inc. has appointed Mr. James Lavender to its Board of Directors following resolutions from the Annual General Meeting held on December 22, 2025. Mr. Lavender and his group were major investors in BioMark's most recent financing, completed in March 2025, underscoring strong insider alignment with the Company's growth strategy as it transitions from development to commercial execution. As BioMark accelerates its U.S. market entry, Mr. Lavender has been instrumental in opening high-level channels with state-level organizations and strategic investment groups across the United States. Mr. Lavender brings extensive software development and enterprise sales experience from leading technology companies, with a particular focus on scaling data-driven platforms. He has been a key advocate for expanding BioMark's use of Artificial Intelligence (AI) and Machine Learning (ML) to enhance clinical performance, automation, and scalability of metabolomics-based oncology diagnostics.
お知らせ • Oct 14Biomark Diagnostics Inc., Annual General Meeting, Dec 22, 2025Biomark Diagnostics Inc., Annual General Meeting, Dec 22, 2025.
お知らせ • May 12Biomark Diagnostics Inc. Announces the Publication of Pivotal Study as Part of the Special Issue Molecular Pathogenesis and Diagnostics of Lung Diseases of the International Journal of Molecular SciencesBioMark Diagnostics Inc. announced the publication of a pivotal study as part of the special issue Molecular Pathogenesis and Diagnostics of Lung Diseases of the International Journal of Molecular Sciences. The research, titled "Clinical Validation of Plasma Metabolite Markers for Early Lung Cancer Detection", provides significant external validation for BioMark's metabolomics and machine learning powered technology, particularly highlighting its high specificity and accuracy in detecting early-stage non-small cell lung cancer (NSCLC) and differentiating it from other non-cancerous lung conditions. The study utilized a large, clinically diverse patient cohort, analyzing 680 archived plasma samples in a discovery cohort and an independent set of 216 plasma samples for validation. A key strength of the research was the composition of the control group, which included not only healthy individuals but also patients with various non-cancerous lung diseases. This design allowed for a rigorous assessment of the test's ability to accurately identify lung cancer, minimizing the potential for false positives due to other lung conditions. The ability to detect lung cancer at its earliest stages significantly improves patient outcomes and survival rates. Current screening methods, such as low dose computed tomography (LDCT), have limitations, including lower sensitivity and specificity compared to regular CT scans, and can result in false positives leading to unnecessary invasive procedures. BioMark's minimally invasive blood test offers a promising approach to complement current screening methods, potentially leading to earlier interventions and better patient prognoses.
お知らせ • Mar 31Biomark Diagnostics Inc. announced that it has received CAD 4.261195 million in fundingOn March 31, 2025, BioMark Diagnostics Inc. closed the transaction. The company announced that it has issued 4,593,984 units at an issue price of CAD 0.30 per unit for gross proceeds of CAD 1,378,195.2 in second and final tranche. The Units were issued at a price of CAD 0.30 per Unit, for aggregate gross proceeds of CAD 4,261,195. Each unit consists of one common share and one full purchase warrant. One whole share purchase warrant will entitle the holder thereof to purchase one common share at CAD 0.50 per share for a period of three years from the closing date of the private placement. The securities issued under the private placement will be subject to a period of four months and one day under the Canadian securities laws and subject to resale restrictions under the U.S. securities laws. Certain Insiders, Directors and Officers subscribed for a portion of this placement. Participation of the insiders of the Company in the private placement. The transaction included participation from United States and Europe. The transaction is oversubscribed.
お知らせ • Mar 27Biomark Diagnostics Inc. announced a financing transactionBiomark Diagnostics Inc. announced a non-brokered private placement that it will issue units to receive funding on March 26, 2025. Each unit consists of one common share of company and one full purchase warrant. One whole share purchase warrant will entitle the holder thereof to purchase one common share at CAD 0.50 per share for a period of three years from the closing date of the private placement. The securities issued under the private placement will be subject to a period of four months and one day under the Canadian securities laws and subject to resale restrictions under the U.S. securities laws. No finders' fees were payable on the private placement. Under the first tranche, the company issued 9,610,000 units at a price of CAD 0.30 per Unit, for aggregate gross proceeds of CAD 2,883,000.
お知らせ • Jan 16Biomark Diagnostics Inc. Announces Publication of Peer-Reviewed Validation of Machine Learning Models for Lung Cancer Detection in Frontiers in OncologyBioMark Diagnostics Inc. announced that its long-term investment in integrating artificial intelligence and machine learning into metabolomic profiling has achieved a major milestone. As the global healthcare investment community is focused on the transformative power of AI at the J.P. Morgan Healthcare Conference, BioMark has received this week notification that its research regarding a machine learning-driven predictive model for lung cancer detection has been accepted for publication in the prestigious, peer-reviewed journal Frontiers in Oncology. The accepted article, titled "Translational impact of machine learning-driven predictive modeling with pathway-based plasma metabolomic biomarkers for lung cancer detection," represents a successful realization of BioMark's strategy to utilize advanced computational tools to enhance diagnostic precision. This achievement validates the company's past capital allocation toward sophisticated AI infrastructure and confirms the scientific rigor of its metabolic pathway analysis. By moving beyond traditional biomarker identification and utilizing pathway-level data, BioMark has demonstrated a more comprehensive way to interpret the metabolic signatures of early-stage lung cancer. This research was made possible through a strategic collaboration with Dr. Maria Vaida and her team at the Harrisburg University of Science and Technology. The publication describes the use of pathway-based features from the Human Metabolome Database (HMDB) and explores the mechanistic drivers of cancer through interpretability tools such as SHAP analysis. This methodological approach allows for a deeper understanding of how specific metabolic pathways, such as those involved in nutrient processing and tumor growth, contribute to diagnostic models. The partnership with Harrisburg University has been instrumental in bridging the gap between complex data science and clinical application, ensuring that BioMark's technological foundation is built upon peer-reviewed, world-class scientific inquiry.
お知らせ • Jan 01Biomark Diagnostics Inc. Appoints James Lavender as Board of Director, Effective December 22, 2025BioMark Diagnostics Inc. has appointed Mr. James Lavender to its Board of Directors following resolutions from the Annual General Meeting held on December 22, 2025. Mr. Lavender and his group were major investors in BioMark's most recent financing, completed in March 2025, underscoring strong insider alignment with the Company's growth strategy as it transitions from development to commercial execution. As BioMark accelerates its U.S. market entry, Mr. Lavender has been instrumental in opening high-level channels with state-level organizations and strategic investment groups across the United States. Mr. Lavender brings extensive software development and enterprise sales experience from leading technology companies, with a particular focus on scaling data-driven platforms. He has been a key advocate for expanding BioMark's use of Artificial Intelligence (AI) and Machine Learning (ML) to enhance clinical performance, automation, and scalability of metabolomics-based oncology diagnostics.
お知らせ • Oct 14Biomark Diagnostics Inc., Annual General Meeting, Dec 22, 2025Biomark Diagnostics Inc., Annual General Meeting, Dec 22, 2025.
お知らせ • May 12Biomark Diagnostics Inc. Announces the Publication of Pivotal Study as Part of the Special Issue Molecular Pathogenesis and Diagnostics of Lung Diseases of the International Journal of Molecular SciencesBioMark Diagnostics Inc. announced the publication of a pivotal study as part of the special issue Molecular Pathogenesis and Diagnostics of Lung Diseases of the International Journal of Molecular Sciences. The research, titled "Clinical Validation of Plasma Metabolite Markers for Early Lung Cancer Detection", provides significant external validation for BioMark's metabolomics and machine learning powered technology, particularly highlighting its high specificity and accuracy in detecting early-stage non-small cell lung cancer (NSCLC) and differentiating it from other non-cancerous lung conditions. The study utilized a large, clinically diverse patient cohort, analyzing 680 archived plasma samples in a discovery cohort and an independent set of 216 plasma samples for validation. A key strength of the research was the composition of the control group, which included not only healthy individuals but also patients with various non-cancerous lung diseases. This design allowed for a rigorous assessment of the test's ability to accurately identify lung cancer, minimizing the potential for false positives due to other lung conditions. The ability to detect lung cancer at its earliest stages significantly improves patient outcomes and survival rates. Current screening methods, such as low dose computed tomography (LDCT), have limitations, including lower sensitivity and specificity compared to regular CT scans, and can result in false positives leading to unnecessary invasive procedures. BioMark's minimally invasive blood test offers a promising approach to complement current screening methods, potentially leading to earlier interventions and better patient prognoses.
お知らせ • Mar 31Biomark Diagnostics Inc. announced that it has received CAD 4.261195 million in fundingOn March 31, 2025, BioMark Diagnostics Inc. closed the transaction. The company announced that it has issued 4,593,984 units at an issue price of CAD 0.30 per unit for gross proceeds of CAD 1,378,195.2 in second and final tranche. The Units were issued at a price of CAD 0.30 per Unit, for aggregate gross proceeds of CAD 4,261,195. Each unit consists of one common share and one full purchase warrant. One whole share purchase warrant will entitle the holder thereof to purchase one common share at CAD 0.50 per share for a period of three years from the closing date of the private placement. The securities issued under the private placement will be subject to a period of four months and one day under the Canadian securities laws and subject to resale restrictions under the U.S. securities laws. Certain Insiders, Directors and Officers subscribed for a portion of this placement. Participation of the insiders of the Company in the private placement. The transaction included participation from United States and Europe. The transaction is oversubscribed.
お知らせ • Mar 27Biomark Diagnostics Inc. announced a financing transactionBiomark Diagnostics Inc. announced a non-brokered private placement that it will issue units to receive funding on March 26, 2025. Each unit consists of one common share of company and one full purchase warrant. One whole share purchase warrant will entitle the holder thereof to purchase one common share at CAD 0.50 per share for a period of three years from the closing date of the private placement. The securities issued under the private placement will be subject to a period of four months and one day under the Canadian securities laws and subject to resale restrictions under the U.S. securities laws. No finders' fees were payable on the private placement. Under the first tranche, the company issued 9,610,000 units at a price of CAD 0.30 per Unit, for aggregate gross proceeds of CAD 2,883,000.
お知らせ • Oct 21Biomark Diagnostics Inc., Annual General Meeting, Dec 27, 2024Biomark Diagnostics Inc., Annual General Meeting, Dec 27, 2024. Location: british columbia, richmond Canada
お知らせ • Sep 10Biomark Diagnostics Completes Testing of over 5,400 Subjects as Part of A Validation Study for Early Lung Cancer DetectionBioMark Diagnostics Inc. announced the successful completion of a significant clinical trial in collaboration with the Institut Universitaire de Cardiologie et de Pneumologie de Quebec. Over 5,400 patient samples were analyzed using BioMark's innovative lung cancer assay, demonstrating the test's potential to revolutionize early detection and improve patient outcomes. BioMark has partnered with a leading data analytics group possessing robust artificial intelligence and machine learning capabilities to analyze the vast amount of data collected during the trial. The results of the study will be presented at an upcoming medical conference and submitted for publication in a peer-reviewed journal. BioMark is committed to advancing the development of its lung cancer assay and making it available to patients in need as soon as possible. This innovative technology has the potential to significantly improve early detection rates and treatment outcomes for this devastating disease.
Reported Earnings • Aug 30First quarter 2025 earnings released: CA$0.007 loss per share (vs CA$0.005 loss in 1Q 2024)First quarter 2025 results: CA$0.007 loss per share (further deteriorated from CA$0.005 loss in 1Q 2024). Revenue: CA$38.3k (down 3.6% from 1Q 2024). Net loss: CA$623.3k (loss widened 49% from 1Q 2024). Over the last 3 years on average, earnings per share has fallen by 1% per year whereas the company’s share price has remained flat.
Reported Earnings • Jul 28Full year 2024 earnings released: CA$0.017 loss per share (vs CA$0.022 loss in FY 2023)Full year 2024 results: CA$0.017 loss per share (improved from CA$0.022 loss in FY 2023). Revenue: CA$163.2k (up 6.3% from FY 2023). Net loss: CA$1.43m (loss narrowed 23% from FY 2023). Over the last 3 years on average, earnings per share has fallen by 5% per year but the company’s share price has increased by 3% per year, which means it is well ahead of earnings.
Reported Earnings • Mar 03Third quarter 2024 earnings released: CA$0.005 loss per share (vs CA$0.005 loss in 3Q 2023)Third quarter 2024 results: CA$0.005 loss per share (in line with 3Q 2023). Revenue: CA$41.5k (up 13% from 3Q 2023). Net loss: CA$406.8k (loss widened 3.3% from 3Q 2023). Over the last 3 years on average, earnings per share has fallen by 13% per year whereas the company’s share price has fallen by 17% per year.
Board Change • Feb 01Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 3 highly experienced directors. Member of Advisory Board AI Berkeley was the last director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.
New Risk • Jan 27New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of German stocks, typically moving 11% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (11% average weekly change). Negative equity (-CA$1.2m). Earnings have declined by 23% per year over the past 5 years. Revenue is less than US$1m (CA$159k revenue, or US$118k). Minor Risks Shareholders have been diluted in the past year (9.1% increase in shares outstanding). Market cap is less than US$100m (€15.1m market cap, or US$16.4m).
New Risk • Jan 05New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 10% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Negative equity (-CA$1.2m). Earnings have declined by 23% per year over the past 5 years. Revenue is less than US$1m (CA$159k revenue, or US$119k). Minor Risks Share price has been volatile over the past 3 months (9.2% average weekly change). Shareholders have been diluted in the past year (10% increase in shares outstanding). Market cap is less than US$100m (€13.6m market cap, or US$14.9m).
お知らせ • Dec 29Biomark Diagnostics Inc. announced that it has received CAD 1.9 million in fundingBiomark Diagnostics Inc announced that it has completed a non-brokered private placement of 7,600,000 units at a price of CAD 0.25 per unit for gross proceeds of CAD 1,900,000 on December 29, 2023. The securities issued under the private placement will be subject to a hold period of four months and one day. Each unit consists of one common share and one-full purchase warrant. One whole share purchase warrant will entitle the holder thereof to purchase one common share at CAD 0.45 per share for a period of three years from the closing date of the private placement, subject to an acceleration clause. Certain Insiders, Directors and Officers subscribed for a portion of this placement. No Finders' fees were payable on the private placement.
Reported Earnings • Nov 29Second quarter 2024 earnings released: CA$0.003 loss per share (vs CA$0.006 loss in 2Q 2023)Second quarter 2024 results: CA$0.003 loss per share (improved from CA$0.006 loss in 2Q 2023). Revenue: CA$42.1k (up 2.9% from 2Q 2023). Net loss: CA$210.5k (loss narrowed 60% from 2Q 2023). Over the last 3 years on average, earnings per share has fallen by 15% per year but the company’s share price has increased by 27% per year, which means it is well ahead of earnings.
お知らせ • Oct 13Biomark Diagnostics Inc., Annual General Meeting, Dec 22, 2023Biomark Diagnostics Inc., Annual General Meeting, Dec 22, 2023.
Reported Earnings • Aug 30First quarter 2024 earnings releasedFirst quarter 2024 results: Revenue: CA$39.7k (up 11% from 1Q 2023). Net loss: CA$418.9k (flat on 1Q 2023). Over the last 3 years on average, earnings per share has fallen by 20% per year but the company’s share price has increased by 13% per year, which means it is well ahead of earnings.
New Risk • Aug 04New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: €8.75m (US$9.65m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-CA$920k free cash flow). Share price has been highly volatile over the past 3 months (16% average weekly change). Negative equity (-CA$1.1m). Earnings have declined by 25% per year over the past 5 years. Revenue is less than US$1m (CA$153k revenue, or US$115k). Market cap is less than US$10m (€8.75m market cap, or US$9.65m).
Reported Earnings • Aug 01Full year 2023 earnings released: CA$0.022 loss per share (vs CA$0.02 loss in FY 2022)Full year 2023 results: CA$0.022 loss per share (further deteriorated from CA$0.02 loss in FY 2022). Revenue: CA$153.5k (up 249% from FY 2022). Net loss: CA$1.84m (loss widened 27% from FY 2022). Over the last 3 years on average, earnings per share has fallen by 17% per year but the company’s share price has only fallen by 6% per year, which means it has not declined as severely as earnings.
お知らせ • Jan 12BioMark Diagnostics Inc. Announces Update from Ongoing Clinical Trial Using its Lung Cancer Liquid Biopsy Test as it Prepares for Commercial LaunchBioMark Diagnostics Inc. announced several updates from ongoing clinical trial using the Company's liquid biopsy test for early cancer detection and monitoring of lung cancer. As clinical trial success relies on effective patient recruitment, BioMark is delighted to announce that enrollment for its pivotal lung cancer screening study exceeded 1,000 participants in less than one year. The lung cancer screening demonstration project led by Dr. Simon Martel, pulmonologist at the Quebec Heart and Lung Institute (Institut Universitaire de Cardiologie et Pneumologie de Québec- Université Laval - IUCPQ-UL), is intended to combine BioMark's metabolomics liquid biopsy test with radiomics and genetics biomarkers to help at-risk Quebecers get access to an accurate and accessible lung cancer screening program. The multimodal study was designed to recruit 4,000 participants from eight major hospitals across in Quebec, generating data that can support BioMark's implementation within the Province of Quebec. The Company also announces its first international patient recruited as part of a European prospective lung cancer screening trial in France known as the ILYAD study. BioMark's blood-based biomarker panel has been selected to define personalized lung cancer risk assessment in Europe's screen-eligible population who are most likely to benefit from a CT scan. The study is being conducted by Pr Sébastien Couraud, pulmonologist at the Hospices Civils de Lyon (HCL) and through a partnership with France- based TransDiag. Through the ILYAD study, the investigators are studying the participation rate during the initial round in the lung cancer screening program and assessing the performance of several blood- based biomarkers for the detection of cancers in screened individuals. The test being developed by the consortium would offer the opportunity to screen nearly 4 million individuals in France who are eligible for lung cancer screening under current European guidelines. These at-risk individuals are aged between 50 and 75 and have a history of heavy smoking. The Company intends to pursue clinical validation of the test as a laboratory developed test (LDT) in parallel with these ongoing studies. The BioMark Lung Cancer Risk Assessment Test will be available through its Quebec-based accredited laboratory, BioMark Diagnostic Solutions Inc., within approximately 9 - 12 months based on the completion of the ISO 15-189 certification.
Is New 90 Day High Low • Mar 03New 90-day high: €0.21The company is up 141% from its price of €0.088 on 03 December 2020. The German market is up 8.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 6.0% over the same period.
